Document Detail

A randomized study of multi-day infusion of autologous peripheral blood progenitor cells.
MedLine Citation:
PMID:  9489643     Owner:  NLM     Status:  MEDLINE    
Peripheral blood progenitor cells (PBPC) are increasingly used as the source of stem cells in both the autologous and allogeneic settings. Based on previous early non-randomized studies reporting enhanced engraftment following fractionated autologous PBPC infusion, some centers and study groups infuse PBPC over 3 days. To study the possible benefit of multiple day PBPC infusion, 60 patients receiving high-dose chemotherapy and autologous progenitor cell transplantation (ABMT) were randomized to receive their PBPC divided over 1, 2 or 3 days. Stem cells were mobilized with G-CSF 5 microg/kg for 7 days and PBPC were collected on days 5-7. Patients received daily G-CSF 5 microg/kg i.v. over 30 min beginning 4 h after the infusion of the first aliquot of PBPCs. Toxicity was similar for the 1, 2 and 3 day infusion groups. The median time to achieve 500 neutrophils/mm3 was 10, 11 and 11 days in the groups receiving PBPCs over 1, 2 or 3 days, respectively. The median time to achieve a platelet count of 20 x 10(9)/l was 11 days for the group receiving their cells as a single infusion and 12 days in the other two groups. We conclude that expanding PBPC infusion over 2 or 3 days does not enhance engraftment or reduce toxicity.
H Abdel-Razeq; B Pohlman; S Andresen; M Kalaycio; B Overmoyer; K Wise; R Dannley; D DeMars; M Goormastic; B Bolwell
Related Documents :
1970963 - Single high doses of cyclophosphamide enable the collection of high numbers of hemopoie...
8497383 - A double-blind randomized crossover study to compare the antiemetic efficacy of 250 mg ...
8891743 - Cardiorenal consequences of dual angiotensin converting enzyme and neutral endopeptidas...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Bone marrow transplantation     Volume:  21     ISSN:  0268-3369     ISO Abbreviation:  Bone Marrow Transplant.     Publication Date:  1998 Feb 
Date Detail:
Created Date:  1998-05-08     Completed Date:  1998-05-08     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8702459     Medline TA:  Bone Marrow Transplant     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  221-3     Citation Subset:  IM    
Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, OH 44195, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antigens, CD34 / analysis
Hematopoietic Stem Cell Transplantation / adverse effects,  methods*
Prospective Studies
Reg. No./Substance:
0/Antigens, CD34

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Electroencephalogram abnormality and high-dose busulfan in conditioning regimens for stem cell trans...
Next Document:  Is in vitro expansion of human cord blood cells clinically relevant?